A Phase 2 interventional study of Apixaban and Apixaban in Atrial Fibrillation, sponsored by Pfizer. Completed at 18 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2013-05-01.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing apixaban in Atrial Fibrillation — 11 open to participants now, 12 under way, 4 of them phase 3. apixaban · Atrial Fibrillation.
Among the 31 studies testing apixaban in Atrial Fibrillation, this one is the 19th largest by enrollment, is the only one that started in 2008, is one of 4 in phase 2, and was the 3rd registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →11 of the 31 studies testing apixaban in Atrial Fibrillation are open now, in 10 countries. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Ages 19+
VA Office of Research and Development · Sites in United States
Ages 22+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 65+
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
Yonsei University · Sites in Korea, Republic of
Ages 19–80
By country, each count listing its studies:
apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 222 is above the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 586 across the 31 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 31 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
15 studies in Atrial Fibrillation by Pfizer: none open now, none under way, none of them phase 3. Of 13 finished, 10 (77%) have results posted.
Among the 15 studies in Atrial Fibrillation by Pfizer, this one is the only one that started in 2008, is the only one in phase 2, and was the 2nd registered.
Pfizer’s Atrial Fibrillation studies by the year they started, since 2000.
2 of the studies testing apixaban in Atrial Fibrillation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03907046Phase 3Yale UniversityAnticoagulation in ICH Survivors for Stroke Prevention and Recovery | 2027-04 |
| NCT03129490Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 31 studies testing apixaban in Atrial Fibrillation, from their registry updates:
Among Pfizer’s 15 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the effect of two doses of Apixaban (2.5 mg BID and 5 mg BID) versus Warfarin on the composite endpoint of major and clinically relevant non-major bleeding during the treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Apixaban
Drug: Apixaban
Drug: Warfarin sodium
Apixaban 5 mg tablet BID for 12 weeks
Apixaban 2.5 mg tablet BID for 12 weeks
At each visit, the subject to take appropriate Warfarin tablet (on investigator's order) once a day every morning for 12 weeks
Number of Participants With Major (Per International Society on Thrombosis and Haemostasis [ISTH] Criteria) or Clinically Relevant Non-major Bleeding Adjudicated by Clinical Event Committee During the Treatment Period
Major bleeding event was acute clinically overt bleeding accompanied by decrease in hemoglobin of 2 g/dL or more over a 24-hour period, transfusion of 2 or more units of packed red blood cells, or bleeding that occurs in critical site (e.g., intracranial). Fatal bleeding was also major bleeding event. Clinical relevant non-major bleeding was acute or sub-acute clinically overt bleeding that does not satisfy the criteria for major bleeding and that leads to either hospital admission for bleeding, physician guided medical or surgical treatment for bleeding or a change in antithrombotic therapy.
Time frame: Baseline to Week 12
Number of Participants With Total Bleeding Events During the Treatment Period
Total bleeding events consisted of major (per International Society on Thrombosis and Haemostasis \[ISTH\] Criteria), clinically relevant non-major and minor bleeding events. All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding were classified as minor bleeding.
Time frame: Baseline to Week 12
Number of Participants With Major (Per International Society on Thrombosis and Haemostasis [ISTH] Criteria) Bleeding Events During the Treatment Period
Major bleeding event is acute clinically overt bleeding accompanied by decrease in hemoglobin of 2 g/dL or more over a 24-hour period, transfusion of 2 or more units of packed red blood cells, or bleeding that occurs in critical site (e.g., intracranial). Fatal bleeding is also major bleeding event.
Time frame: Baseline to Week 12
Number of Participants With Clinically Relevant Non-major Bleeding Events During the Treatment Period
Clinical relevant non-major bleeding was acute or sub-acute clinically overt bleeding that does not satisfy the criteria for major bleeding and that leads to either hospital admission for bleeding, physician guided medical or surgical treatment for bleeding or a change in antithrombotic therapy.
Time frame: Baseline to Week 12
Number of Participants With Stroke or Systemic Embolism During the Intended Treatment Period
The definition of the "Intended Treatment Period" was the period starting on the day of randomization and ending at the later one of either 2 days after the last dose of the study drug or Day 85/Week 12 after the randomization day.
Time frame: Baseline to Week 12
Number of Participants With Stroke, Systemic Embolism, or All-Cause Death During the Intended Treatment Period
The definition of the "Intended Treatment Period" was the period starting on the day of randomization and ending at the later one of either 2 days after the last dose of the study drug or Day 85/Week 12 after the randomization day.
Time frame: Baseline to Week 12
Number of Participants With Myocardial Infarction or All-Cause Death During the Intended Treatment Period
The definition of the "Intended Treatment Period" was the period starting on the day of randomization and ending at the later one of either 2 days after the last dose of the study drug or Day 85/Week 12 after the randomization day.
Time frame: Baseline to Week 12
Mean Plasma Apixaban Concentration at Each Time Point in Participants Treated With Apixaban
Sample at 4 hours postdose was to be taken if possible.
Time frame: 0, 2, 4 hours postdose at Week 1 and Week 8
Mean Prothrombin Time (PT) at Each Time Point in Participants Treated With Apixaban
Sample at 4 hours postdose was to be taken if possible.
Time frame: Week 0, 0, 2, 4 hours postdose at Week 1 and Week 8
Mean Prothrombin Time-International Normalized Ratio (PT-INR) at Each Time Point in Participants Treated With Apixaban
Blood sample at 4 hours postdose was collected if possible. PT-INR is a standardized measure derived from prothrombin time (PT). The systematic variations in PT assay results are corrected in PT-INR in order to optimize measurements of vitamin K antagonists.
Time frame: Week 0, 0, 2, 4 hours postdose at Week 1 and Week 8
Mean Activated Partial Thromboplastin Time (aPTT) at Each Time Point in Participants Treated With Apixaban
Blood Sample at 4 hours postdose was collected if possible. The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V, VIII, IX, X, XI and XII. Higher values than the baseline indicate anticoagulant effects.
Time frame: Week 0, 0, 2, 4 hours postdose at Week 1 and Week 8
Mean Anti-Xa Activity (Apixaban Units) at Each Time Point in Participants Treated With Apixaban
Blood sample at 4 hours postdose was collected if possible. Below the limit of quantification (BLQ) was assigned the value 0 for calculation. If 50% or more of the data was BLQ, statistics was not be calculated. Therefore, 0 means not calculated.
Time frame: Week 0, 0, 2, 4 hours postdose at Week 1 and Week 8
Mean Prothrombin Fragment 1+2 (F1+2) at Each Time Point in Participants Treated With Warfarin or Apixaban
Below the limit of quantification (BLQ) was assigned the value 0 for calculation. If 50% or more of the data was BLQ, statistics was not calculated. Therefore, 0 indicates not calculated.
Time frame: Week 0, Week 1, Week 8
Mean D-Dimer at Each Time Point in Participants Treated With Warfarin or Apixaban
Below the limit of quantification (BLQ) was assigned the value 0 for calculation.
Time frame: Week 0, Week 1, Week 8
| Milestone | Warfarin | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Started | 75 | 72 | 71 |
| Completed | 66 | 65 | 66 |
| Not completed | 9 | 7 | 5 |
| Withdrew: Adverse event | 4 | 4 | 4 |
| Withdrew: Physician decision | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 |
| Withdrew: Dosing incorrect study durg | 2 | 0 | 0 |
Major bleeding event was acute clinically overt bleeding accompanied by decrease in hemoglobin of 2 g/dL or more over a 24-hour period, transfusion of 2 or more units of packed red blood cells, or bleeding that occurs in critical site (e.g., intracranial). Fatal bleeding was also major bleeding event. Clinical relevant non-major bleeding was acute or sub-acute clinically overt bleeding that does not satisfy the criteria for major bleeding and that leads to either hospital admission for bleeding, physician guided medical or surgical treatment for bleeding or a change in antithrombotic therapy.
| participants | Warfarin | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Number of Participants With Major (Per International Society on Thrombosis and Haemostasis [ISTH] Criteria) or Clinically Relevant Non-major Bleeding Adjudicated by Clinical Event Committee During the Treatment Period | 4 | 1 | 1 |
Total bleeding events consisted of major (per International Society on Thrombosis and Haemostasis \[ISTH\] Criteria), clinically relevant non-major and minor bleeding events. All acute clinically overt bleeding events not meeting the criteria for either major bleeding or clinically relevant non-major bleeding were classified as minor bleeding.
| participants | Warfarin | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Number of Participants With Total Bleeding Events During the Treatment Period | 13 | 9 | 17 |
Major bleeding event is acute clinically overt bleeding accompanied by decrease in hemoglobin of 2 g/dL or more over a 24-hour period, transfusion of 2 or more units of packed red blood cells, or bleeding that occurs in critical site (e.g., intracranial). Fatal bleeding is also major bleeding event.
| participants | Warfarin | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Number of Participants With Major (Per International Society on Thrombosis and Haemostasis [ISTH] Criteria) Bleeding Events During the Treatment Period | 1 | 0 | 0 |
Clinical relevant non-major bleeding was acute or sub-acute clinically overt bleeding that does not satisfy the criteria for major bleeding and that leads to either hospital admission for bleeding, physician guided medical or surgical treatment for bleeding or a change in antithrombotic therapy.
| participants | Warfarin | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Number of Participants With Clinically Relevant Non-major Bleeding Events During the Treatment Period | 3 | 1 | 1 |
The definition of the "Intended Treatment Period" was the period starting on the day of randomization and ending at the later one of either 2 days after the last dose of the study drug or Day 85/Week 12 after the randomization day.
| participants | Warfarin | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Number of Participants With Stroke or Systemic Embolism During the Intended Treatment Period | 3 | 0 | 0 |
The definition of the "Intended Treatment Period" was the period starting on the day of randomization and ending at the later one of either 2 days after the last dose of the study drug or Day 85/Week 12 after the randomization day.
| participants | Warfarin | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Number of Participants With Stroke, Systemic Embolism, or All-Cause Death During the Intended Treatment Period | 3 | 0 | 0 |
The definition of the "Intended Treatment Period" was the period starting on the day of randomization and ending at the later one of either 2 days after the last dose of the study drug or Day 85/Week 12 after the randomization day.
| participants | Warfarin | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Number of Participants With Myocardial Infarction or All-Cause Death During the Intended Treatment Period | 0 | 0 | 0 |
Sample at 4 hours postdose was to be taken if possible.
| ng/mL | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|
| 0 hour post dose at Week 1 (n=68, 70) | 53.31 ± 28.55 | 119.34 ± 50.83 |
| 2 hours post dose at Week 1 (n=68, 70) | 99.43 ± 44.65 | 201.80 ± 95.58 |
| 4 hours post dose at Week 1 (n=38, 35) | 104.09 ± 44.48 | 224.40 ± 77.06 |
| 0 hour post dose at Week 8 (n=67, 66) | 62.83 ± 37.27 | 137.79 ± 54.91 |
| 2 hours post dose at Week 8 (n=67, 66) | 120.16 ± 57.79 | 250.53 ± 81.35 |
| 4 hours post dose at Week 8 (n=35, 29) | 110.58 ± 49.96 | 244.55 ± 84.27 |
Sample at 4 hours postdose was to be taken if possible.
| second | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|
| Week 0 (n=72, 71) | 14.54 ± 2.20 | 14.41 ± 2.06 |
| 0 hour post dose at Week 1 (n=67, 70) | 12.22 ± 1.56 | 12.54 ± 0.79 |
| 2 hours post dose at Week 1 (n=68, 70) | 12.46 ± 0.72 | 13.28 ± 1.05 |
| 4 hours post dose at Week 1 (n=38, 35) | 12.36 ± 0.67 | 13.48 ± 0.82 |
| 0 hour post dose at Week 8 (n=67, 66) | 12.09 ± 0.73 | 12.74 ± 0.87 |
| 2 hours post dose at Week 8 (n=67, 66) | 12.68 ± 0.82 | 13.83 ± 1.03 |
| 4 hours post dose at Week 8 (n=35, 29) | 12.47 ± 0.75 | 13.85 ± 1.07 |
Blood sample at 4 hours postdose was collected if possible. PT-INR is a standardized measure derived from prothrombin time (PT). The systematic variations in PT assay results are corrected in PT-INR in order to optimize measurements of vitamin K antagonists.
| International normalized ratio | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|
| Week 0 (n=72, 71) | 1.76 ± 0.46 | 1.72 ± 0.43 |
| 0 hour post dose at Week 1 (n=67, 70) | 1.30 ± 0.37 | 1.34 ± 0.15 |
| 2 hours post dose at Week 1 (n=68, 70) | 1.33 ± 0.14 | 1.48 ± 0.21 |
| 4 hours post dose at Week 1 (n=38, 35) | 1.30 ± 0.12 | 1.51 ± 0.18 |
| 0 hour post dose at Week 8 (n=67, 66) | 1.27 ± 0.14 | 1.38 ± 0.17 |
| 2 hours post dose at Week 8 (n=67, 66) | 1.37 ± 0.16 | 1.61 ± 0.20 |
| 4 hours post dose at Week 8 (n=35, 29) | 1.34 ± 0.15 | 1.59 ± 0.22 |
Blood Sample at 4 hours postdose was collected if possible. The aPTT is a screening test for the intrinsic pathway and is sensitive for deficiencies of Factors I, II, V, VIII, IX, X, XI and XII. Higher values than the baseline indicate anticoagulant effects.
| Second | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|
| Week 0 (n=72, 71) | 34.51 ± 5.05 | 32.98 ± 4.39 |
| 0 hour post dose at Week 1 (n=67, 70) | 33.26 ± 10.24 | 33.24 ± 4.28 |
| 2 hours post dose at Week 1 (n=68, 70) | 33.04 ± 3.57 | 35.19 ± 4.42 |
| 4 hours oist dose at Week 1 (n=38, 35) | 32.00 ± 3.49 | 35.36 ± 5.44 |
| 0 hour post dose at Week 8 (n=67, 66) | 33.83 ± 5.18 | 35.65 ± 4.32 |
| 2 hours post dose at Week 8 (n=67, 66) | 34.67 ± 4.39 | 37.92 ± 4.78 |
| 4 hours post dose at Week 8 (n=35, 29) | 32.75 ± 3.86 | 36.46 ± 5.19 |
Blood sample at 4 hours postdose was collected if possible. Below the limit of quantification (BLQ) was assigned the value 0 for calculation. If 50% or more of the data was BLQ, statistics was not be calculated. Therefore, 0 means not calculated.
| ng/mL | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|
| Week 0 (n=72, 71) | 0 ± 0 | 0 ± 0 |
| 0 hour post dose at Week 1 (n=68, 69) | 45.29 ± 26.77 | 111.19 ± 49.02 |
| 2 hours post dose at Week 1 (n=68, 70) | 94.90 ± 45.23 | 187.58 ± 85.72 |
| 4 hours post dose at Week 1 (n=38, 35) | 99.07 ± 44.46 | 213.24 ± 67.54 |
| 0 hour post dose at Week 8 (n=67, 65) | 56.81 ± 37.34 | 130.12 ± 52.20 |
| 2 hours post dose at Week 8 (n=67, 66) | 114.97 ± 56.25 | 236.36 ± 88.08 |
| 4 hours post dose at Week 8 (n=35, 29) | 103.61 ± 44.54 | 237.78 ± 78.58 |
Below the limit of quantification (BLQ) was assigned the value 0 for calculation. If 50% or more of the data was BLQ, statistics was not calculated. Therefore, 0 indicates not calculated.
| pmol/L | Warfarin | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Week 0 (n=75, 72, 71) | 144.0 ± 345.2 | 0 ± 0 | 91.4 ± 115.3 |
| Week 1 (n=75, 68, 70) | 100.4 ± 139.0 | 133.8 ± 105.5 | 137.0 ± 255.5 |
| Week 8 (n=68, 67, 66) | 0 ± 0 | 152.9 ± 79.7 | 121.1 ± 56.3 |
Below the limit of quantification (BLQ) was assigned the value 0 for calculation.
| ng/mL | Warfarin | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Week 0 (n=75, 72, 71) | 240.4 ± 333.5 | 297.8 ± 634.6 | 196.4 ± 181.4 |
| Week 1 (n=75, 68, 70) | 245.2 ± 325.7 | 209.9 ± 202.6 | 237.0 ± 314.3 |
| Week 8 (n=68, 67, 66) | 209.9 ± 201.1 | 227.0 ± 253.5 | 203.5 ± 190.6 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Warfarin | — | 4/75 (5.3%) | 17/75 (22.7%) |
| Apixaban 2.5mg BID | — | 1/72 (1.4%) | 24/72 (33.3%) |
| Apixaban 5.0 mg BID | — | 5/71 (7%) | 22/71 (31%) |
| Event | Warfarin | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| Cerebral infarctionNervous system disorders | 2/75 | 0/72 | 0/71 |
| Accidental overdoseInjury, poisoning and procedural complications | 1/75 | 0/72 | 1/71 |
| OverdoseInjury, poisoning and procedural complications | 0/75 | 0/72 | 1/71 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/75 | 0/72 | 1/71 |
| Back painMusculoskeletal and connective tissue disorders | 0/75 | 0/72 | 1/71 |
| Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/75 | 0/72 | 1/71 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/75 | 0/72 | 1/71 |
| Arterial stenosis limbVascular disorders | 0/75 | 1/72 | 0/71 |
| Subarachnoid haemorrhageNervous system disorders | 1/75 | 0/72 | 0/71 |
| Event | Warfarin | Apixaban 2.5mg BID | Apixaban 5.0 mg BID |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 7/75 | 8/72 | 8/71 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 4/75 | 4/72 | 4/71 |
| Blood urine presentInvestigations | 4/75 | 1/72 | 3/71 |
| DiarrhoeaGastrointestinal disorders | 0/75 | 3/72 | 1/71 |
| Atrial fibrillationCardiac disorders | 0/75 | 0/72 | 2/71 |
| Oedema peripheralGeneral disorders | 0/75 | 0/72 | 2/71 |
| ContusionInjury, poisoning and procedural complications | 1/75 | 0/72 | 2/71 |
| FallInjury, poisoning and procedural complications | 0/75 | 0/72 | 2/71 |
| Blood creatine phophkinase increasedInvestigations | 0/75 | 2/72 | 2/71 |
| HaematuriaRenal and urinary disorders | 1/75 | 0/72 | 2/71 |
| Age Continuous(years) | Warfarin | Apixaban 2.5mg BID | Apixaban 5.0 mg BID | Total |
|---|---|---|---|---|
| Mean | 71.7 ± 7.0 | 69.3 ± 8.4 | 70.0 ± 8.1 | 70.3 ± 7.9 |
| Sex: Female, Male(Participants) | Warfarin | Apixaban 2.5mg BID | Apixaban 5.0 mg BID | Total |
|---|---|---|---|---|
| Female | 14 | 11 | 13 | 38 |
| Male | 60 | 63 | 61 | 184 |
The record gives a start of Jun 2008, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban